@article{article, title  = {{Efficacy and safety of dupilumab in children aged 6–11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year}},

 url = {{}},

 year = {{2022}},

 month = {{4}},

 author = {{Cork MJ and Guttman-Yassky E and Simpson EL and Soong W and Wang Z and Chuang CC and O’malley JT and Bansal A}},

 doi = {{10.1016/j.reval.2022.02.078}},

 volume = {{62}},

 journal = {{Revue Française d'Allergologie et d'Immunologie Clinique}},

 issue = {{3}},

 pages = {{321}},

 note = {{Accessed on 2024/12/22}}}